Company Profile
Nuvalent Stock Price, News & Catalysts
- Ticker:
- NUVL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for NUVL.
Company overview
Precision Oncology Company
Nuvalent develops highly selective small-molecule kinase inhibitors for cancers with established oncogenic drivers. Its design strategy aims to overcome resistance mutations, penetrate the central nervous system, avoid off-target toxicities, and produce durable responses in patients with advanced solid tumors.
ROS1 Program
Zidesamtinib is a ROS1-selective inhibitor developed for ROS1-positive non-small cell lung cancer, including tumors with resistance mutations and brain metastases. The program includes an initial application for previously treated patients and a label-expansion strategy for patients who have not received a prior ROS1 inhibitor.
ALK Program
Neladalkib is an ALK-selective, TRK-sparing inhibitor designed for advanced ALK-positive non-small cell lung cancer. Development spans previously treated patients and the Phase 3 ALKAZAR study comparing neladalkib with alectinib in the first-line setting.
HER2 and Discovery Pipeline
NVL-330 targets HER2 alterations and is being evaluated in the HEROEX-1 Phase 1 study. Earlier discovery programs apply Nuvalent's structure-based chemistry approach to additional validated kinase targets where existing therapies are limited by resistance, brain penetration, or tolerability.
Acquisition by GSK
GSK subsequently agreed to acquire Nuvalent, adding the company's precision-oncology portfolio and kinase-design capabilities to a larger global oncology organization. The transaction links Nuvalent's late-stage assets with GSK's regulatory, manufacturing, and commercial infrastructure.
Future catalysts
- FDA PDUFA decision for zidesamtinib in previously treated ROS1-positive non-small cell lung cancer on September 18, 2026.
- Submission of data supporting a zidesamtinib label expansion in TKI-naive ROS1-positive non-small cell lung cancer in the second half of 2026.
- FDA review of the submitted NDA for neladalkib in previously treated ALK-positive non-small cell lung cancer.
- Disclosure of a new development candidate by year-end 2026.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Nuvalent (NUVL)?
Nuvalent (NUVL) most recently closed at 123.96 USD, a +0.02% move versus the previous session.
What is the market cap of Nuvalent (NUVL)?
Nuvalent currently has a market capitalization of 7.22B USD on BioPharmSignal.
What does Nuvalent do?
Precision Oncology Company Nuvalent develops highly selective small-molecule kinase inhibitors for cancers with established oncogenic drivers. Its design strategy aims to overcome resistance mutations, penetrate the central nervous system, avoid off-target toxicities, and produce durable responses in patients with advanced solid tumors. ROS1...
On which exchange is NUVL stock listed?
Nuvalent (NUVL) is associated with NASDAQ, United States, Biopharma.
What is NVL-330?
HER2 and Discovery Pipeline NVL-330 targets HER2 alterations and is being evaluated in the HEROEX-1 Phase 1 study.
Which conditions is Nuvalent targeting with NVL-330?
Nuvalent is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Nuvalent describe recent progress with NVL-330?
FDA PDUFA decision for zidesamtinib in previously treated ROS1-positive non-small cell lung cancer on September 18, 2026. Submission of data supporting a zidesamtinib label expansion in TKI-naive ROS1-positive non-small cell lung cancer in the second half of 2026. FDA review of the submitted NDA for neladalkib in previously treated ALK-positive non-small...
What is HEROEX-1?
HER2 and Discovery Pipeline NVL-330 targets HER2 alterations and is being evaluated in the HEROEX-1 Phase 1 study.